Poster above created for PNARS by Crystal Mathews
Animal are not predictive models for human drug or disease response — 95% of drugs that pass animal tests fail or cause harm in human trials.
IMBRUVICA (ibrutinib) – Risk of Serious and Fatal Cardiac Arrhythmias or Cardiac Failure – 2022-08-29
BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular Occlusion – 2022-02-03
PAXLOVID (nirmatrelvir and ritonavir) – Dosing and Dispensing in Renal Impairment, Risk of Serious Adverse Reactions Due to Drug Interactions – 2022-01-17
MedEffect e-Notice: Ombrelle Garnier Complete Dry Mist Spray Sunscreen recalled due to elevated benzene levels
MedEffect e-Notice on AstraZeneca COVID-19 Vaccine and COVISHIELD, notice from Health Canada distributed by email, June 29, 2021.
Health Canada has initiated a safety review on Xeljanz and Xeljanz XR (tofacitinib), used to treat arthritis and ulcerative colitis, From Government of Canada, Recalls and Safety Alerts, April 6, 2021
Drug Safety Advisories: A Need for International Coordination, From Therapeutics Initiative, Dec. 3, 2020.
Drug Picato has been withdrawn from use in Canada due to potential increased risk of skin cancer. From Government of Canada, Recalls and safety alerts, October 27, 2020.
health-product-infowatch-november-2020-health-canada
progressiveresearchsociety.com 